VENUS MEDTECH-B (02500) saw its intraday surge exceed 14%. As of the time of writing, the stock was up 7.99%, trading at HK$3.65, with a turnover of HK$26.2799 million. On January 14 local time, Cardiovalve, a subsidiary of Hangzhou-based VENUS MEDTECH, jointly with MTH IP, L.P., filed a patent infringement lawsuit against global heart valve giant Edwards Lifesciences in the US District Court for the District of Delaware. The lawsuit alleges that Edwards' core product, the PASCAL Precision transcatheter valve repair system, infringes upon US Patent No. 10,702,385 ("the '385 patent"), which is owned by Cardiovalve. Analysts pointed out that this legal action represents proactive rights protection by VENUS MEDTECH following its successful defense of the '385 patent's validity against a challenge from Edwards in July 2025. This move is not only a defense of its own innovative achievements but also a landmark case in the globalization of Chinese medical device companies, demonstrating competitive market participation underpinned by a robust intellectual property system.